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Introduction: Standardization of mesenchymal stromal cells (MSCs) manufacturing is urgently needed to enable
translational activities and ultimately facilitate comparison of clinical trial results. In this work we describe the
adaptation of a proprietary method for isolation of a specific umbilical cord tissue-derived population of MSCs,
herein designated by its registered trademark as UCXW, towards the production of an advanced therapy medicinal
product (ATMP).
Methods: The adaptation focused on different stages of production, from cell isolation steps to cell culturing and
cryopreservation. The origin and quality of materials and reagents were considered and steps for avoiding
microbiological and endotoxin contamination of the final cell product were implemented. Cell isolation efficiency,
MSCs surface markers and genetic profiles, originating from the use of different medium supplements, were
compared. The ATMP-compliant UCXW product was also cryopreserved avoiding the use of dimethyl sulfoxide, an
added benefit for the use of these cells as an ATMP. Cells were analyzed for expansion capacity and longevity. The
final cell product was further characterized by flow cytometry, differentiation potential, and tested for contaminants
at various passages. Finally, genetic stability and immune properties were also analyzed.
Results: The isolation efficiency of UCXW was not affected by the introduction of clinical grade enzymes.
Furthermore, isolation efficiencies and phenotype analyses revealed advantages in the use of human serum in cell
culture as opposed to human platelet lysate. Initial decontamination of the tissue followed by the use of
mycoplasma- and endotoxin-free materials and reagents in cell isolation and subsequent culture, enabled the
removal of antibiotics during cell expansion. UCXW-ATMP maintained a significant expansion potential of 2.5
population doublings per week up to passage 15 (P15). They were also efficiently cryopreserved in a DMSO-free
cryoprotectant medium with approximately 100% recovery and 98% viability post-thaw. Additionally, UCXW-ATMP
were genetically stable upon expansion (up to P15) and maintained their immunomodulatory properties.
Conclusions: We have successfully adapted a method to consistently isolate, expand and cryopreserve a
well-characterized population of human umbilical cord tissue-derived MSCs (UCXW), in order to obtain a cell prod-
uct that is compliant with cell therapy. Here, we present quality and safety data that support the use of the UCXW
as an ATMP, according to existing international guidelines.* Correspondence: rita.barcia@ecbio.com
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The public clinical trials database [1] currently shows
approximately 130 open clinical trials using mesenchy-
mal stromal cells (MSCs) for a very wide range of thera-
peutic applications, the majority of which are in Phase I
(safety studies), Phase II (efficacy studies) or combined
Phase I/II studies. Clinical trials using MSCs are showing
promising results. This has resulted in an increase in de-
mand for the development of production processes in
accordance with guidelines for Good Manufacturing
Practices (GMP), to guarantee reliability of the cells for
the purpose of their use in clinical studies and ultim-
ately, the advancement of stem cell-based therapies (for
an extensive review, see [2]).
Due to the novelty, complexity and technical specifi-
city of cell therapy, specially tailored and harmonized
regulations were necessary to ensure global availability
of cellular products. Currently, in the European Union,
the regulation (EC) No. 1394/2007 on Advanced Ther-
apy Medicinal Products (ATMPs) lays down specific
guidelines concerning centralized authorization, supervi-
sion and pharmacovigilance.
One of the most important requirements of ATMPs is
the full characterization of the product. Safety is a major
concern with this type of biopharmaceutical. The cell-
based product must not cause infections, allergies or
malignancies. To verify this, numerous quality control
steps need to be implemented within the manufacturing
process, including microbiological testing (to detect
viral, fungal, mycoplasma or contamination with other
bacteria) and pyrogenicity testing. In addition, a pheno-
type analysis must also be performed in order to assess
identity and the degree of purity of the cell population
as well as additional safety testing, including genetic sta-
bility and tumorigenicity (even if human MSCs are
thought not to transform in vivo) [3,4].
In addition to safety, cell number is another major
concern in cell-based products since a significant num-
ber of functional cells is needed for clinically relevant
cell dosages. Recent clinical trials have used minimum
multiple dosages of 1 to 2 × 106 cells/kg of body weight
for graft-versus-host disease in transplant patients [5],
myocardial infarction [6] and in the treatment of Crohn’s
disease [7].
The umbilical cord is a rich source of MSCs which,
unlike other sources, does not require invasive harvest-
ing procedures. Because of their multi/pluripotency, im-
munomodulatory and homing properties, as well as their
capacity to produce valuable cytokines and/or growth
factors, these cells are interesting candidates for thera-
peutic applications in immune-related disorders and re-
generative medicine [8,9].
We developed and patented an isolation method that
consistently isolates MSCs from the umbilical cordtissue that meet the International Society for Cellular
Therapy (ISCT) guideline criteria [10]. The cell-based
product was registered under the UCXW trademark.
UCXW isolated using this patented method have proven
to be able to induce immune tolerance in vivo by repres-
sing T-cell activation and promoting the expansion of
Tregs, and in a chronic adjuvant induced arthritis model,
animals treated with UCXW showed faster remission of
local and systemic arthritic manifestations [9].
In the present work, we adapted our proprietary
method for the production of UCXW so they can be cer-
tified as an ATMP, both for autologous and allogeneic,
off-the-shelf, cell therapy applications. The adaptation
occurred at different stages of production, from cell iso-
lation steps to cell culturing and cryopreservation. The
cell product that resulted from the selected method was
finally termed UCXW-ATMP, and was characterized in
terms of cell identity, purity (microbiological, identity
and viability), tumorigenicity and genetic stability. Some
general potency assays were also performed confirming




This study was performed in accordance with the
Declaration of Helsinki and approved by the Ethics
Committee at the Cascais Hospital Dr. José de Almeida.
Umbilical cord donations were obtained with written in-
formed consents according to Directive 2004/23/EC of
the European Parliament (Portuguese Law 22/2007 of
June 29).
Isolation of UCXW and UCXW-ATMP
Human umbilical cord tissue MSCs were isolated ac-
cording to a proprietary method [10]. The resulting cell
product is termed UCXW. The ATMP adaptation of this
method focused on different stages of manufacturing: 1)
an initial decontamination step was introduced, using an
efficient antibiotic/antimycotic solution in order to avoid
the use of antibiotics and antimycotics in the cell culture
medium during the expansion step; 2) clinical grade en-
zymes were used and fetal bovine serum (FBS) substi-
tutes were introduced to improve safety of the cellular
product; and 3) sample handling materials and the na-
ture of cell culture reagents were altered to ensure a
mycoplasma- and endotoxin-free cellular product.
For the isolation of UCXW, umbilical cord sections,
from either vaginal or caesarean delivery, were trans-
ported to the laboratory facilities and processed within a
period up to 72 hours after collection. The umbilical
cords were immersed in a decontaminating solution
overnight at 4°C prior to processing. The cords were
washed and the outer amniotic membrane removed.
Martins et al. Stem Cell Research & Therapy 2014, 5:9 Page 3 of 15
http://stemcellres.com/content/5/1/9Transversal sections of 2.5 cm were then digested with a
mixture of either: 1) standard crude collagenase, type II
(Sigma-Aldrich), and porcine trypsin (Sigma-Aldrich),
the herein named enzyme research grade method (ENZ
(RG)), or 2) GMP grade equivalent collagenase and
animal component free TrypLE™ Select (GibcoW, Life
Technologies™, Carlsbad, CA, USA), the herein named
enzyme clinical grade method (ENZ(CG)).
An optimized precise proportion among tissue mass,
enzyme activity units, digestion solution volume and void
volume was used for the isolation of cells from the umbil-
ical cord tissue. A total of 17.5 g of umbilical cord was
processed per isolation (on average, 1 cm corresponds to
1 g of UC tissue). Cells from both the first and second
recovery phases (as described in Santos et al., 2006 [10])
were joined together and used as a single culture. After di-
gestion, static horizontal incubation and centrifugation, the
cell suspension was incubated in static monolayer culture
flasks (Nunc, Thermo Fisher Scientific, Roskilde, Denmark)
at 37°C in a humidified atmosphere containing 7% CO2
in basal MSC culture medium (α-MEM basal medium
with 1 g/L glucose and 2 mM glutamine (Sigma-Aldrich®,
St. Louis, MO, USA)) supplemented with either 20%
FBS (Invitrogen™, Life Technologies™, Carlsbad, California,
USA), 20% human serum (HS) (Lonza, Walkersville, MD,
USA) or 20% human Platelet Lysate (hPL) (provided by the
©Karolinska Institutet, Stockholm, Sweden, SE).
Platelet lysate was prepared in-house from five to six buf-
fycoats (containing SSP + additive solution, Macopharma,
Tourcing, France) from A+ donors and plasma. Human
serum (Lonza) was obtained from human AB blood from
normal human donors who tested negative for hepatitis B
surface antigen (HbsAG), antibodies to hepatitis C (HCV),
and human immunodeficiency virus I and II (HIV-I and
HIV-II). Sera were pooled and sterile filtered.
After overnight incubation, non-adherent cells were
removed and fresh medium was added. Cultures were
maintained and a complete change of culture medium
was performed twice weekly. Fibroblast-like colonies
were observed regularly and passaged when 80 to 90%
confluence was observed.
Cells were detached using either 0.25% (w/v) Trypsin-
EDTA (Sigma-Aldrich), in the ENZ(RG) protocols, or
with TrypLE™ Select (Gibco) in the ENZ(CG) protocols.
MSC medium was added and cells counted and seeded
at 5,000 to 10,000 cells/cm2 on culture flasks (Nunc).
Cells were placed at 37°C, 7% CO2 in a humidified incu-
bator, and fed by replacing the culture medium twice
weekly until 80 to 90% confluence.
For the ATMP-adapted protocols, all autoclaved glass-
ware material was substituted with plastic ware and all
sample handling and cell culture materials were certified
to be mycoplasma-free and certified as having an endo-
toxin level <0.1 EU/mL.Cultures were monitored on a regular basis for the vis-
ible detection of bacterial or fungal contaminations.
Near confluent cell culture supernatants were collected
at different passages and analyzed for mycoplasma and
endotoxin contamination using the LookOutW Myco-
plasma PCR Detection Kit (Sigma-Aldrich) and the
Limulus Amebocyte Lysate (LAL) PYROGENTW Plus
(Lonza) respectively, according to the manufacturer’s
instructions.
Expression profiling
Total RNA from UCXW cultivated in MSC-medium sup-
plemented with FBS, HS or hPL was isolated using the
RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) follow-
ing the protocols of the manufacturer. About 5 × 106
cells were collected after trypsinization. After cell lysis,
homogenization was performed by passing the lysate five
times through a 20-gauge syringe and DNAse digestion
was used to eliminate DNA contamination. Quality and
integrity of the total RNA isolated was controlled on
a bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA).
Total RNA, weighting 5 μg, was used for biotinylated
target synthesis according to standard protocols supplied
by the manufacturer (Affymetrix, Santa Clara, CA, USA).
Briefly, RNA was converted to dsDNA using 100 pmol
of a T7T23V primer (Eurogentec, Seraing, Belgium) con-
taining a T7 promoter. The cDNA was then used directly
in an in vitro transcription reaction in the presence
of biotinylated nucleotides. The concentration of biotin-
labeled cRNA was determined by UV absorbance. For
hybridization, 10 μg of each biotinylated cRNA prepar-
ation were fragmented and placed in a hybridization
cocktail containing also four biotinylated hybridization
controls (BioB) as recommended by the manufacturer.
Samples were hybridized for 16 hours to Affymetrix
Gene Chip HG_U133 Plus 2.0, representing about
47,000 human transcripts. After hybridization the
GeneChips were washed, stained with SA-PE and read
using an Affymetrix GeneChip fluidic station and
scanner.
The resulting dataset is available under Gene Expres-
sion Omnibus (GEO) accession number GSE51869.
Analysis of microarray data was performed using the
Affymetrix Microarray Suite 5.0 and BRB Array Tools
4.2. All array experiments were normalized using Robust
Multi-array Average. Correlation of expression profiles
from differentially cultivated UCXW cells was done using
BRB Array Tools and visualized as scatter plots.
Immune phenotypic analyses
To analyze cell-surface expression of typical MSC sur-
face marker proteins, cells were detached, counted
and labeled with the following anti-human antibody
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PerCp/Cy5.5; CD45 - PerCp/Cy5.5; CD31 - FITC; CD34 -
FITC; CD19 - Pacific Blue; HLA-DR - Pacific Blue (all
from Biolegend) and also CD105 PE (eBioscience, Inc.,
San Diego, CA, USA). The mouse isotype antibodies used
as the respective controls were: Pacific Blue IgG1; Pacific
Blue IgG2a; IgG1k PerCp/Cy5.5; IgG2a PerCp/Cy5.5;
IgG1k PE; IgG1k APC and IgG1k FITC (all from Biole-
gendW, San Diego, CA, USA). A total of 10,000 labeled
cells were acquired using a Gallios Flow cytometer
(Beckman Coulter) and results analyzed with Kaluza
software (Beckman Coulter, Inc., Carlsbad, CA, USA).
Cryopreservation of UCXW and UCXW-ATMP
Approximately 3 × 106 cells were centrifuged at 200 g, at
4°C for 10 minutes and UCXW were resuspended in
1 mL of 90% (v/v) FBS (Invitrogen) with 10% (v/v)
DMSO (Sigma-Aldrich) and UCXW-ATMP in Biofreeze
(Biochrom, Merck Millipore, Berlin, Germany). Cells
were cryopreserved using a Controlled Rate Freezer
(CRF) (IceCube14S, Sylab, Neupurkersdorf, Austria) and
a freezing profile adapted from Freimark in 2011 [11].
Thawing of UCXW and UCXW-ATMP
Cryovials were removed from the liquid N2 container
and placed immediately in the water bath at 37°C until
cell suspension was almost entirely thawed. Cell suspen-
sion was then diluted one-tenth with pre-warmed MSC
medium, counted and plated in a culture flask (Nunc) at
approximately 20,000 cells/cm2 and placed in a humidi-
fied incubator at 37°C, 7% CO2.
Differentiation of UCXW-ATMP
Adipogenic differentiation was induced by cyclic changes
of induction and maintenance media in cells cultivated
post-confluence as previously described [9]. After three
cycles of media changes, adipogenic differentiation was
apparent by intracellular accumulation of lipid-rich vac-
uoles that stained with Oil Red O.
To promote chondrogenic differentiation, cell pellets
were prepared and cultured for three weeks in complete
chondrogenic differentiation medium, as previously de-
scribed [9]. After the culture period, fixed, deparaffinized
and rehydrated sections were stained with 1% (w/v)
alcian blue (Sigma-Aldrich) in 3% (v/v) acetic acid
(Sigma-Aldrich) and bright blue stained glycosaminogly-
cans and mucopolysaccharides were visible.
Osteogenic induction medium was used to promote
differentiation as previously described [9]. The onset of
osteoblast formation was evaluated after four weeks by
the detection of alkaline phosphatase activity using the
leukocyte alkaline phosphatase-kit (Sigma-Aldrich) ac-
cording to the manufacture’s protocol.MSC karyotyping and evaluation of teratoma-forming
potential
Freshly thawed UCXW-ATMP cells were cultured over-
night using the above mentioned culture conditions with
the addition of colchicine (Sigma-Aldrich) at a final con-
centration of 5 μg/mL. Cells were then washed and re-
suspended with hypotonic (0.56%) potassium chloride
solution for 10 minutes and then fixed in acetic acid:
methanol at a 1:3 ratio. Slides were then flame-dried to
improve the spread of the chromosomes.
The conventional Q-banding technique was used ac-
cording to the International System for Human Cyto-
geneic Nomenclature, ISCN 2005, and cytogeneic analysis
was performed with a Cytovision Image analysis system
(Applied Imaging, Santa Clara, CA, USA). A total of 20
metaphases were analyzed. Two cells with identical struc-
tural abnormalities, two with identical supernumerary
chromosomes or three with the same missing chromo-
somes were considered to constitute an abnormal clone.
The teratoma formation assays with UCXW-ATMP were
conducted in the Animal Centre of the Karolinska
Institutet (SE), a licensed animal research facility and was
approved by the ethics committee of South Stockholm
under the number S166/01. A total of 12 immunodeficient
male, C.B.-17/GbmsTac-scid-bgDF N7 mice (six weeks
old), were obtained from M&B, Ltd., Ry (Denmark) and
kept under isolated conditions in M2 cages on aspen wood
chips (Beekay bedding, Scanbur B&K AB, Karlslunde,
Denmark) with free access to water and rodent diet, using
artificial light from 6:00 to 18:00, Room temperature:
24 ± 2°C, and humidity: 55 ± 10%. Briefly, cells were
thawed 16 hours prior to implantation and approximately
1 × 104 cells were implanted beneath the testicular
capsule of a young (six-week) SCID/Beige male mouse
anesthetized using isoflurane (Baxter, Deerfield, IL, USA).
Human embryonic stem cell line H-9 was used as a
positive control. Teratoma growth was determined by pal-
pation and the mice were sacrificed (cervical dislocation)
6.5 to 8.5 weeks post implantation. The tissue was fixed in
4% neutral buffered formaldehyde overnight, dehydrated
through a graded series of alcohols to xylene, and embed-
ded in paraffin.
Mixed lymphocyte reaction
Peripheral blood samples were obtained from healthy vol-
unteers of both genders after informed consent. Blood
was collected, diluted 1:1 (v/v) with PBS (1×) and mixed
with half the volume of HistopaqueW-1077 (Sigma-Al-
drich). Peripheral blood mononucleated cells (PBMCs)
were collected from the Ficoll gradient after centrifugation
at 720 g for 30 minutes at RT.
The Mixed Lymphocyte Reaction (MLR) was per-
formed in 96-well microtiter plates using RPMI (Gibco)
and 5% HS obtained from the specific donor. The
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2 ×105 cells per well. Stimulator cells (UCXW or UCXW-
ATMP) were irradiated with 50 Gy (Gammacell ELAN
3000, Best Theratronics, Ltd., Ottawa, Ontario, Canada)
prior to addition to the culture, at 20,000 cells per well.
Quadruplicate cultures were performed for each condi-
tion. Cultures were incubated at 37°C in 5% CO2 for six
days, pulsed with [3H]thymidine (1 microCi per well,
Amersham Biosciences, Piscataway, NJ, USA) for 16
hours, and the cells were harvested onto filter mats
using a Tomtec 96-well cell harvester (Perkin Elmer).
Radioactivity incorporated into the dividing cells was de-
termined using a scintillation counter (Microbeta Trilux
Scintillation and Luminescence Counter 145 LSC, Perkin
Elmer, Waltham, MA, USA).
Immune suppression assay
The immune suppression assay was performed in 96-
well microtiter plates using RPMI (Gibco) supplemented
with 5% HEPES (Gibco), 5% Pen-Strep (Gibco), 5%
NaPyr (Gibco) and 5% human serum obtained from the
specific donor. The PBMCs were obtained from two dif-
ferent donors and cultured at 2 × 105 cells per well and
were stimulated with anti-CD3 (eBioscience), anti-CD28
(eBioscience) and IL-2 (eBioscience). Suppressor cells
(UCXW or UCXW-ATMP), were irradiated with 50 Gy
(Gammacell ELAN 3000, Best Theratronics) prior to
addition to the culture at 50,000 cells per well. Quad-
ruplicate cultures were performed for each condition.
Cultures were incubated at 37°C in 5% CO2 for six
days, pulsed with [3H]thymidine (1 microCi per well,
Amersham Biosciences, Piscataway) for 16 hours, and
the cells were harvested onto filter mats using a Tomtec
96-well cell harvester (Perkin Elmer). Radioactivity incor-
porated into the dividing cells was determined using a
scintillation counter (Microbeta Trilux Scintillation and
Luminescence Counter 145 LSC, Perkin Elmer).
Treg conversion assay
PBMCs were collected and washed with PBS containing
2% FCS and then stained with mAbs against human
CD3, CD4 and CD25 (eBioscience) for cell sorting. The
purified CD3+CD4+CD25- T-cells were cultured in plate-
bound αhuCD3 (2.5 μg/mL, eBioscience) in 96-well flat-
bottom plates in the following conditions. Briefly, 1 ×
105 purified T-cells/well were cultured in the presence
of 2 μg/mL αhuCD28 (eBioscience), 20 U/mL huIL-2
(Peprotech®, Rocky Hill, NJ, USA) and 10 ng/mL TGF-β
(R&D Systems®, Minneapolis, MN, USA) or the indi-
cated UCXW (irradiated as described), in replacement of
TGF-β, in a ratio of 1:1 to the T-cells. All conditions
were performed in triplicate wells. After five days in cul-
ture at 37°C with 5% CO2, cells were stained with mAbs
against human CD3, CD4 and CD25 (eBioscience) andthen stained for huFoxp3 as described by the manufac-
turer (eBioscience). The analysis was performed on the
converted CD3+CD4+CD25+Foxp3+ regulatory T-cells.
Results
Evaluation of candidate UCXW-ATMP isolation protocols
ECBio has previously developed a reproducible technol-
ogy for the isolation, culture and cryopreservation of a
specific population of umbilical cord tissue-derived
MSCs [10]. This cell product was characterized previ-
ously according to the ISCT guidelines [12] and the
resulting product recently registered with the UCXW
trademark. In this study, various steps of the original
manufacturing process were adapted to be in conformity
with European Medicines Agency (EMA)’s quality and
safety guidelines in order to allow for the clinical use of
the UCXW cell product as an ATMP. Namely, clinical
grade (CG) enzymes were incorporated to replace re-
search grade (RG) enzymes in the digestion process and
the isolated cells cultured in FBS substitutes, such as
hPL and HS. Sample handling and cell culture materials
and solutions were also altered in order to deter possible
microbiological and pyrogenic contaminations. For the
purpose of this work, the original manufacturing process
is referred to as ENZ(RG) FBS, the manufacturing
process involving clinical grade enzymes and human
serum is referred to as ENZ(CG) HS, and the manufac-
turing process involving clinical grade enzymes and hu-
man platelet lysate is referred to as ENZ (CG) hPL (see
the Materials and methods section).
A pre-evaluation of the storage/decontamination time
and temperature was performed by a paired analysis of
UCs (n = 5). Results showed that, for a successful decon-
tamination, an overnight storage at 4°C is more effective
(100% decontamination) than incubation for one hour at
37°C (80% decontamination). Both storage/decontamin-
ation methods used did not cause any significant alter-
ations in the average number of cells collected at P0 or
in the necessary time to reach confluence. However, al-
terations in cell yield occurred when cords were stored
for over 72 hours.
The effects of changing the digestion enzymes and
serum supplements were also evaluated. For that pur-
pose, the yields of the different isolation methods were
analyzed and compared. The digestion of the umbilical
cords using RG and CG reagents, followed by culture of
isolated cells in FBS provided similar cell yields, indicat-
ing that the introduction of CG enzymes alone does
not affect the method’s isolation efficiency (Figure 1). In
contrast, cell isolation and subsequent culture in the
presence of the FBS substitutes, HS or hPL, showed a
significant decrease (P <0.01) in cell yields, namely, a 4-
fold reduction with HS and a dramatic 68-fold decrease
with hPL (Figure 1). This result suggests that the
Figure 1 Isolation of UCXW cells. A standard protocol using a
mixture of crude collagenase and porcine trypsin for cell isolation
(ENZ(RG)), and fetal bovine serum (FBS) for cell culture was adapted
by replacing the digestion enzymes with clinical grade enzymes
(ENZ(CG)) and culturing the cells in human serum (HS) or human
Platelet Lysate (hPL). The efficiency of the process was plotted taking
into consideration the total cells at the end of passage 0 (P0)
isolated from a standard cord (17.5 g, considering an average
weight of 1 gram per centimeter of cord), and the days to
confluence. Results are represented as mean ± SEM.
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fected by the FBS substitutes. For hPL cultures, there were
visibly less adherent cells on the day after isolation in com-
parison with the cells cultured in HS. Since so few cells
were scattered throughout the culture surface, they
formed confluent clusters and not a homogeneous mono-
layer and consequently, cells took significantly longer to
reach local confluence at the end of passage 0 (P0), that is,
to undergo the initial selection phase of adherence and
then grow and multiply. Interestingly, when cells from
three different cords isolated with FBS containing media
were thawed at different passage numbers (p5, p10 e
p15) and cultured in hPL supplemented media, prolifer-
ation was slightly higher in hPL-containing cultures when
compared to FBS (see Additional file 1: Figure S1). We,
therefore, speculate that the observed reduced isolation
efficiency in hPL-supplemented cultures is associated
with poor initial cell adherence and not with proliferation.
In HS cultures, an extended number of days was re-
quired for the cultures to reach confluence at P0 (17 days,
Figure 2), suggesting that UCXW had longer duplication
times in HS than in FBS. An Affymetrix gene expression
array (HG U133 Plus 2.0, representing >47,000 transcripts)
was used to compare the gene expression profiles of the
cell populations obtained when cells are cultured in the
FBS substitutes. Results showed that the expression pro-
files of the cells from both HS and hPL cultures were gen-
erally similar (ρ >0.96) in comparison to those from the
ENZ(RG) FBS protocol (Figure 3A, B). However, whencultures in hPL were compared to cultures in FBS (from
the same cord), 1,103 probe sets (683 genes) were found
to be regulated more than two-fold. A total of 488
genes were down-regulated and according to Database for
Annotation, Visualization and Integrated Discovery
(DAVID)-Functional Annotation Clustering these are
mostly enriched for “tube formation-lung development,
cell migration and differentiation”. Of the genes that were
up-regulated (195 genes), most were enriched for “extra-
cellular protein and adhesion” matches.
When cultures in HS were compared to cultures in FBS
(from the same cord) the signals from 803 probe sets (cor-
responding to 517 genes) were altered more than two-
fold. A total of 372 gene transcripts were down-regulated
and 195 gene transcripts were up-regulated. According to
DAVID-Functional Annotation Clustering, the down-
regulated genes were mostly enriched for “cell cycle, regu-
lation, transcription”, potentially connected to slower
growth, whereas the up-regulated genes were mostly
enriched for matches within the “extracellular matrix”
functional annotation group.
A narrower analysis of the expression signals resulting
from probe sets for MSC relevant genes involved in im-
mune regulation, antigen presentation, growth control
and MSC markers also revealed a more prominent gene
expression down-regulation effect in UCXW grown in
hPL than in HS (Figure 3C, D). Table 1 summarizes the
genes with more than two-fold altered expression in
both FBS substitutes. In this cluster, we observed that
the expression of seven genes was altered when FBS was
substituted by HS, while the use of hPL resulted in
double the number of genes with altered expression.
The hPL-specific down-regulation of certain genes,
such as CCL5, FGF2 and PTGES (which regulates the
expression of PGE2), could partially compromise the po-
tential therapeutic effects attributed to MSCs through
paracrine recruitment of resident MSCs, angiogenesis
and immunosuppression, respectively [13-17]. If we con-
sider FBS cultures as a reference (with proven thera-
peutic effects) [9], these results indicate that a greater
similarity was observed when cells are cultured in HS.
Flow cytometric analysis, performed at the end of P0,
demonstrated that cells from the ENZ(CG) HS, ENZ(CG)
hPL protocols and ENZ(RG) FBS cultured cells, all express
the surface marker profile defined by the ISCT for MSCs
(>95% positive for the surface markers CD105, CD90 and
CD73 and <2% for CD45, CD34, CD14, CD19 and HLA-
DR). Additionally, CD44, a mediator protein of cell-to-cell
interactions, cell adhesion and migration, generally associ-
ated with MSC phenotype was also highly expressed in all
UCXW cell populations analyzed. hPL-cultured cells did,
however, show a slight but significant increase in HLA-DR
expression; although cells remained <2% positive for this
surface marker (Figure 4A). More notably, the ENZ(CG)
A B
Figure 2 Cell isolation yields. (A) Cell isolation yield in cells/g of cord (left y axis) and in cells per cord (17.5 g) (right y axis) at the end of
passage 0 (P0) and (B) time necessary for the culture to reach confluence. Results are represented as mean ± SEM.
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of cells expressing CD31, a platelet endothelial cell adhe-
sion molecule. Although not an ISCT MSC requisite, it is
generally accepted that MSCs are devoid of this endothe-
lial marker [18,19]. CD31 positive cells were detected in
ENZ(CG) hPL-derived cells at P0, P1 and P5, though
showing a markedly decreasing trend in CD31 expression
with each cell passage, and reaching levels below 2% by P5
(Figure 4B).
The hPL-induced changes observed in surface marker ex-
pression corroborated the gene expression profiling in the
sense that UCXW undergo greater gene expression devia-
tions from the original ENZ(CG) FBS population when cul-
tured in medium with hPL in comparison to HS.
Such divergence could have a negative impact on
UCXW therapeutic value. Thus, due to higher phenotypic
similarities and yields with the ENZ(RG) FBS protocol,
for which the resulting UCXW have already shown prom-
ising pre-clinical outcomes in inflammatory arthritis
models [9], we have selected ENZ(CG) HS protocol to
be the basis of the UCXW-ATMP manufacturing.
However, before definitively committing to the ENZ
(CG) HS protocol, the efficiency of the decontamina-
tion steps implemented during UCXW isolation and
also throughout the UCXW expansion with regards to
mycoplasma and other bacteria, fungi and endotoxins was
tested. These are frequent laboratory contaminants that
are clinically associated with infection, inflammation
and fever in patients. We found that upon arrival, most
umbilical cords contained significant bacterial and fungal
contaminants, most frequently E. coli, Streptococcus sp.
and Staphylococcus coagulase negative bacteria (data not
shown). The initial decontamination step of the protocol
was, therefore, fundamental to its success. For the final
protocol, only material and reagents that were endotoxin-
free were used throughout the isolation and cell expan-
sion. Quality control points were set at various passages
and detection assays performed to each corresponding
sample. While 75% and 100% of the cultures of UCXWderived from ENZ(RG) FBS protocol were endotoxin posi-
tive at P0 and P1, respectively (n = 6); no contamination
was detected in UCXW-ATMP, derived from ENZ(CG)
HS, until at least P20 (cultures tested every five passages;
n = 20 - sensitivity 0.12 EU/mL). Furthermore, since no
bacterial or fungal contaminations were detected in
UCXW-ATMP samples derived from the ENZ(CG) HS
protocol, we considered the decontamination step applied
to be sufficient to ensure a contaminant-free UCXW prod-
uct. Therefore, cells from P0 onwards were expanded in
antibiotic/antimycotic free media, an added measure to
comply with more strict local authority requirements for a
given ATMP to reach the clinic. These results confirm
that the efforts in material and reagent selection per-
formed were successful in the prevention of microbial,
mycoplasma and endotoxin contamination of the final
UCXW product.
Based on accumulated evidence related to cell yields,
phenotypes, transcriptome profiles and level of microbi-
ologic and endotoxin contaminations, we have finally se-
lected the ENZ(CG) HS protocol to be the basis of the
UCXW-ATMP manufacturing, and thus subjected the
resulting cells to further characterization.
Further characterization of UCXW-ATMP derived from the
ENZ(CG) HS protocol
Quality data
Similar to UCXW, the isolation of UCXW-ATMP is a ro-
bust and efficient protocol; a 97% success rate for isola-
tion and expansion was obtained from a statistically
relevant UC sample population (n = 28).
UC samples have an intrinsic variability that we do not
control. The composition of each cord varies according to
time of gestation, mother’s genetic inheritance, sample
manipulation and storage post-partum and so on. These
differences cause an intrinsic variation in the number of
primary cells isolated from the tissue. Notwithstanding,
cell isolation is almost always guaranteed, with an average
of 1.63 × 105 cells/g obtained immediately following UC
Figure 3 Gene expression profiles of UCXW cultured in HS (A, C) and hPL (B, C) versus FBS. Scatterplots for all genes represented on the
HG-U133Plus2.0 array (A, B) or 132 selected MSC-relevant gene sets representing surface markers and immune suppression related genes (C, D)
are shown. Mean Spearman pairwise correlation coefficients (ρ) are indicated. FBS, fetal bovine serum; hPL, human Platelet Lysate; HS,
human serum.
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http://stemcellres.com/content/5/1/9digestion (and before cell adherence to the plastic surface).
Cell viability at this stage averages 93%. This population is
extremely heterogeneous, with a MSC surface marker pro-
file far from meeting the minimum ISCT criteria (Add-
itional file 2: Table S1). However, after plastic adherence,
which remains one of the most important steps to isolate
MSCs [2], a more pure cell population is obtained, in full
agreement with the ISCT MSC criteria over various pas-
sages (up to P20) (see below). Furthermore, cells were
regularly seeded and cell viability determined at each seed-
ing point by trypan blue exclusion. Viability afterdetachment was systematically >90%. Hence, at the end of
P0, UCXW-ATMP is a relatively homogeneous MSC cell
population.
With this method, an average of 3 × 106 UCXW-ATMP
cells (about 170,000 cells/g cord), was obtained at the end
of passage 0, within an average time of 17 days (Figure 5).
Comparison of UCXW and UCXW-ATMP was per-
formed at later passages with respect to cell expansion
potential and stability. Results showed that cells grow at
a steady rate. Although lagging with respect to UCXW,
UCXW-ATMP propagated well, with growth rates
Table 1 Gene expression in cells cultured with HS or hPL as substitutes of FBS
Gene name Symbol >two-fold change >two-fold change
HS-FBS hPL-FBS
chemokine (C-C motif) ligand 5 CCL5 ↓
fibroblast growth factor 2 (basic) FGF2 ↓
fibroblast growth factor 7 FGF7 ↓ ↓
hepatocyte growth factor (hepapoietin A; scatter factor) HGF ↓ ↓
insulin-like growth factor binding protein 5 IGFBP5 ↓
interleukin 1, beta IL1B ↓ ↓
interleukin 6 (interferon, beta 2) IL6 ↓ ↓
keratinocyte growth factor-like protein 2 KGFLP2 ↓
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog KIT ↓
prostaglandin E synthase PTGES ↓
fibroblast growth factor 5 FGF5 ↑
latent transforming growth factor beta binding protein 2 LTBP2 ↑
5′-nucleotidase, ecto (CD73) NT5E ↓
platelet derived growth factor D PDGFD ↑
platelet-derived growth factor receptor, alpha polypeptide PDGFRA ↑
prostaglandin E receptor 4 (subtype EP4) PTGER4 ↑
transforming growth factor, beta receptor II (70/80 kDa) TGFBR2 ↑
FBS, fetal bovine serum; hPL, human Platelet Lysate; HS, human serum.
163 Affymetrix-clustered genes described to be involved in immune regulation, antigen presentation, growth control, and MSC markers were analyzed.
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week presenting a considerable longevity in culture,
allowing for very high cell expansion potential (an aver-
age of passage 18, after 30 ± 10 PDs and 96 ± 25 days in
culture) (Figure 6A, B).
Furthermore, the MSC surface marker expression profile
of UCXW-ATMP was compliant with ISCT guidelines for at
least 20 passages (Figure 6C, D) and their differentiation
potential was maintained to at least P15 (Figure 7). The fact
that UCXW-ATMP cells can undergo considerable expan-
sion, maintaining their expected MSC phenotype,Figure 4 Flow cytometric analysis of cell surface markers in cell popu
passage 0). Comparison of (A) ISCT minimal MSC markers, including CD44
passage 5, from the various protocols. Results are represented as mean ± S
serum; ISCT, International Society for Cellular Therapy; MSC, mesenchymal sincluding tri-lineage differentiation potential, is of
great importance considering the high cell number re-
quired for their use in a clinical setting which often
implies the establishment of master and working cell
banks.
Safety data
Together with efficacy, the absence of risk for the recipi-
ent’s safety is of most importance for ATMP certification
and market authorization for a cellular product. In this
study we addressed genetic stability, potential forlations isolated and cultured in FBS, hPL and HS (at the end of
and (B) the CD31 endothelial marker from passage 0 through to
EM. FBS, fetal bovine serum; hPL, human Platelet Lysate; HS, human
tromal cell.
Figure 5 Isolation of UCXW and UCXW-ATMP. (A) Comparison of the cell yield in number of cells per gram (g) of UC (left Y-axis) and total cells
obtained per UC (right Y-axis) and (B) days required to reach confluency (end of P0). Results are represented as mean ± SEM.
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http://stemcellres.com/content/5/1/9teratoma formation, as well as possible effects upon allo-
geneic administration (immune response).
To confirm the genetic stability of UCXW-ATMP through-
out the expansion process, cells were analyzed at the cyto-
genetic level at various passages. Analysis (20 metaphases)
confirmed that no significant chromosomal aberrations were
found up to P15 (Figure 8). Furthermore, UCXW-ATMP
cells implanted beneath the testicular capsule of youngFigure 6 UCX® and UCX®-ATMP characterization. (A) Population doubli
passages 1 to 20. UCX®-ATMP propagated well, with growth rates ranging
considerable longevity in culture, allowing for very high cell expansion pot
P20 and reached a maximum passage of P25 after 54 ± 10 PDs and 112 ± 21
stromal cell (MSC) markers of UCX® (A) and UCX®-ATMP (B) at passages 1, 10
also determined. Results are represented as mean ± SEM.SCID/Beige mice confirmed the lack of teratoma-forming
potential of these cells for at least 8.5 weeks. While UCXW-
ATMP cell-implanted animals were 100% negative for tera-
toma formation, positive control human embryonic stem
cells (H-9) induced teratomas in 80% of the control group
test animals (data not shown).
Lymphocyte proliferation assay measures the ability of
lymphocytes to undergo proliferation when stimulatedng rate and (B) cumulative population doublings of cells from
between 1.5 to 3.5 population doublings (PDs)/week presenting a
ential. The comparative control UCX®, grew at 3 - to 6 PDs/week until
days in culture. Flow cytometric analysis of ISCT defined mesenchymal
and 20. The percentage of CD44 and CD31, common MSCs markers, was
Figure 7 Differentiation potential of UCXW-ATMP. Cells underwent differentiation at low and high passages as detected by the respective
biochemical staining; Oil red O staining for adipogenic (bar = 100 μm), Alcian Blue staining for chondrogenic and Alkaline Phosphatase activity
staining for osteogenic differentiation (bar = 200 μm).
Figure 8 G-banding analysis of UCX®-ATMP at P7. Normal
karyotype 2n = 23, autosomal and sex chromosomes.
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http://stemcellres.com/content/5/1/9in vitro by a foreign molecule, antigen or mitogen. Im-
munogenicity of UCXW-ATMP was measured by the
level of proliferation of PBMCs in co-culture. Mixed
lymphocyte stimulation reactions were performed with
two different donors in order to reduce the probability
of HLA matching between responders (PBMCs) and
stimulators (UCXW-ATMP) (Figure 9). The effect of high
and low passage UCXW-ATMP was assessed and
lymphocyte proliferation measured. UCXW derived from
the ENZ(RG) FBS protocol were also included as a com-
parative control [9]. Results showed that UCXW-ATMP
did not elicit lymphocyte activation at any level, indicating
low immunogenicity. Furthermore, basal proliferation of
lymphocytes was reduced when in culture with UCXW-
ATMP, suggesting an UCXW-ATMP-mediated an im-
munosuppressive effect in the culture environment.
This was confirmed with immunosuppression assays by
using either co-cultured UCXW (as a comparative con-
trol) or UCXW-ATMP with CD3, CD28 and IL2 activated
PBMCs, again from two different donors, and measuring
lymphocyte proliferation (Figure 10A). Results clearly
showed that just like UCXW, UCXW-ATMP are im-
munosuppressive. This immunoregulatory property
was also observed in a Treg (CD3+CD4+CD25+Foxp3+)
conversion assay, where the presence of UCXW-ATMP re-
sulted in a significant conversion of the CD4+ cells to CD4+CD25+Foxp3+Tregs (Figure 10B). Together, these
results confirmed that UCXW-ATMP are not only non-
immunogenic, an essential characteristic for future allo-
geneic application in cell therapies, but are also capable of
suppressing the immune system by 1) inhibiting T cell
proliferation and 2) inducing Tregs.
Cryopreservation and recovery of UCXW-ATMP
The isolation method herein described allows for the
harvesting of a substantial amount of UCXW-ATMP that
are easily expanded in culture, reaching clinically
Figure 9 Allogeneic lymphocyte stimulation reaction of UCXW
and UCXW-ATMP. Peripheral blood mononucleated cells (PBMCs) of
donor 1 (filled bars) and donor 2 (open bars) were co-cultivated with
PMBCs, UCXW and UCXW-ATMP at high (P15) and low (P5) passage
(HP and LP). Proliferation was measured through a [3H]thymidine
incorporation assay and results are expressed in counts per minute
(CPM). Basal proliferation level is marked at approximately 5,000
CPM. Results are represented as mean ± SEM.
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cryopreservation is fundamental for proper recovery
prior to future applications. For the UCXW-ATMP, the
aim was to maintain a FBS-free cellular product and re-
move potentially hazardous substances such as DMSO.
We, therefore, implemented the use of BiofreezeW, an
animal component-free, DMSO-free cryopreservation
solution. A controlled rate freezer (CRF) was used and
the most optimal cryopreservation profile was selected
(comparative results not shown). The CRF protocol
adapted from Freimark et al., 2011, along with the use
of Biofreeze, was selected since the resulting viable cellFigure 10 Immunosuppression of UCXW and UCXW-ATMP. (A) Suppres
activated peripheral blood mononucleated cells (PBMCs) from two differen
product (ATMP) and measuring lymphocyte proliferation (B) Treg conversio
CD3+CD4+CD25- T-cells and comparing the percentage of converted CD3+
control) or induced conversion with TGFβ. Results are represented as meanrecovery rate was 98%, comparable to the research grade
cryopreservation using FBS and DMSO. Thawed UCXW-
ATMP adhered to the plastic surface of the culture
flasks and maintained a cell morphology similar to cells
prior to cryopreservation. Furthermore, cells grew to
confluence (within three to five days) and maintained a
typical growth rate of 3.0 PDs/week. Additionally, post-
thawed UCXW-ATMP maintained the MSC phenotype
regarding cell surface markers and differentiation poten-
tial (data not shown).
Discussion
The increasing number in clinical trials involving stem
cell therapies over the last few years is helping to shape
the regulatory demands for emergent new medicines.
However, there is still a lack of definitive standards for
the production of clinical-grade cell products. In fact,
according to EMA’s Directive 2001/83/EC applied to
Advanced Therapy Medicinal Products (EMA/CAT/
CPWP/686637/2011 - Committee for Advanced Therap-
ies (CAT)), the concept behind ATMP development
should not be based on fixed pre-established criteria. In-
stead, and due to the diversity and complexity of cell
based biopharmaceuticals, the strategy should be further
adaptable to a case-by-case basis, always keeping in
mind a strict focus on risk assessment towards safety to
the end user.
In the case of UCXW, adaptation to ATMP-compliant
conditions started with an effective decontamination
procedure of the tissue source by using an antibiotic and
antimycotic solution. This allowed for the removal of
these agents from the subsequent isolation and cell ex-
pansion steps. GMP-compatible and clinical-grade mate-
rials and reagents were introduced. Endotoxin andsion of T cell activation was assayed by incubating CD3, CD28 and IL2
t donors with irradiated UCXW and UCXW- advanced therapy medicinal
n was measured in the same cells by culturing irradiated cells with
CD4+CD25+Foxp3+ regulatory T-cells with unstimulated cells (negative
± SEM.
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isolation and culture procedures. More specifically, a re-
search grade, crude collagenase, known to contain endo-
toxins, non-specific peptidases and xenoproteins [20],
was replaced with a defined, clinical grade enzyme, with-
out compromising cell yield. Trypsin, an animal derived
enzyme, was also replaced by animal origin-free TrypLE
Select. Though FBS is currently used in cell cultures in
ongoing clinical trials, its use is controversial. EMA has
particular concerns regarding the use of FBS due to the
widespread presence of bovine spongiform encephalop-
athy and the potential contamination of samples. Also,
growing evidence shows that the presentation of FBS
proteins, such as albumin, to the recipient immune sys-
tem may result in subsequent antibody-based responses
with the risk of serum sickness [21]. Therefore, in the
likelihood that FBS be excluded for use in clinical prod-
ucts, and foreseeing a future clinical application of
UCXW, HS and hPL substitutes were introduced and
tested in both the initial isolation steps and cell expan-
sion. Results showed that both substitutes affected yield.
In BM-MSCs, hPL has been shown to enhance prolifera-
tion when compared to FBS [22-24]. In growing cultures
of UCXW cells, hPL had a similar effect (Additional file
1: Figure S1) but isolation efficiency was seriously com-
promised when hPL was used immediately following UC
digestion. Despite inducing an up-regulation of genes re-
lated to adhesion (and initial up-regulation of CD31 pro-
tein expression, see Figure 4), hPL seems to mainly
affect cell adhesion upon UC digestion, which ultimately
affects yield. While in hPL-supplemented cultures, re-
duced cell isolation efficiency was associated with poor
initial cell adherence, in HS supplemented cultures, it
was associated with slower proliferation. Indeed, the
proliferation rate of UCXW-ATMP cells was slightly
lower than UCXW (Figure 6A). The latter was consistent
with the DAVID-Functional Annotation Clustering ana-
lysis showing that the down-regulated genes in HS cul-
tures were mostly enriched for matches within the “cell
cycle, regulation, transcription” functional annotation
group.
Despite lower proliferation after cell isolation, HS al-
lows for efficient cell isolation, comparable to that of our
research-grade protocol. The use of HS is associated
with the humanization of the culture, a clear advantage
over the use of FBS, and a viable option for the isolation
and initial culture of UCXW in xenofree conditions.
Interestingly, it has also been suggested that HS main-
tains MSCs in a more primitive stage [25]. Issues con-
cerning variability and limited availability, often
associated with the use of HS, can be overcome by the
use of large, pre-tested, donor pools that can be better
adjusted for a predefined quality as an “off the shelf”
product. Most commonly, serum from AB donors areused to avoid the presence of isoagglutinins, more as a
precaution, since MSCs do not appear to express ABO
blood group antigens [26]. For the pathogen screening
of the serum, quarantine storage can in part overcome
the risk of the diagnostic window. This will allow a re-
test of the blood donor after a second donation, and
after a time interval of at least four months. Only those
units derived from donors verified, after the second do-
nation, to be negative for human infectious disease
markers can then be pooled and used [27]. Various
pathogen-reduction strategies to treat blood products
are also under investigation [28].
FBS substitution for HS resulted in a down-regulation
of important immune-related genes, such as HGF,
IGFBP5, IL1B and IL6 (Table 1). In addition, expansion
of MSCs could compromise immune properties [29]
and could potentially induce genomic aberrations. None-
theless, much like UCXW, UCXW-ATMP showed low
immunogenicity (Figure 9) and were found to be im-
munosuppressive (Figure 10), despite passage number
(data not shown). Further, UCXW-ATMP presented no
apparent safety concerns upon expansion in that no
genomic aberrations were detected up to passage 15
(Figure 8) and no tumorigenicity (teratoma formation)
potential was exhibited. The latter is not surprising in
light of recent data showing that though MSCs are re-
cruited to tumor sites, no increase in leukemia relapse
has been reported after MSC-treatment in graft-versus-
host disease (GvHD) [30]. Also, since the first clinical
trial in humans using MSCs in 1995, tumors have never
been reported [2].
Finally, long-term storage of cells is critical to ensure a
reliable supply for health care providers. The majority of
published work is based on cryopreservation of cells in
DMSO as a cryoprotectant agent, often in combination
with FBS. Although DMSO is used routinely, it has poten-
tial adverse effects on the recipient and may not be opti-
mal for all cells [31]. Furthermore, FBS is also associated
with potential contaminations and immune response risks
as previously noted. In addition, most academic laborator-
ies store cryopreserved cells submerged in liquid nitrogen,
which is not a feasible option for GMP-grade cell products
due to high risk of cross-contamination [32]. Instead,
GMP guidelines demand that cells must be maintained in
liquid nitrogen vapor-phase individual containers. Taking
into consideration these safety and storage factors, cryo-
preservation of UCXW-ATMP was optimized using a
therapy-grade, animal component-free and DMSO-free
cryopreservation product, allowing for GMP-adaptable
conditions for UCXW-ATMP cryopreservation in N2 vapor
phase. Most importantly, thawed UCXW-ATMP maintain
ISCT guideline criteria for MSCs, as well as the associated
safety aspects and, therefore, these conditions can be used
for the establishment of a UCXW-ATMP cell bank.
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Overall, our process upgrade results demonstrate the sta-
bility and safety of UCXW-ATMP as a cell product and
support the use of these cells as an ATMP active sub-
stance. For a prospective clinical use of UCXW-ATMP, fur-
ther potency assays will be used with a given application
in mind. Ideally, these tests should be standardized and
validated quantitative tests as it has been proposed for
bone marrow-derived and adipose tissue-derived MSCs
[33].
Additional files
Additional file 1: Figure S1. Cumulative population doublings of
UCXW from three different cords isolated with FBS containing media.
Additional file 2: Table S1. Flow cytometric analysis of cell surface
markers in UCXW-ATMP immediately after isolation.
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